Feasibility of Molecular Biology in Pancreatic Cyst Tumors

NAActive, not recruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

December 31, 2017

Study Completion Date

January 31, 2027

Conditions
Pancreatic CystPancreas CystSerous CystadenomaMucinous CystadenomaIPMN
Interventions
GENETIC

Molecular biology analysis of pancreatic intra-cyst fluid

"The EUS FNA will be performed according to the Francophone Club of Echo Endoscopy recommendations.~For molecular biology technique, the samples will be processed within the UMR\_S910 unit. Nucleic acids will be extracted from the intra-cystic fluid or, for post-operative patients, from a resected specimen that will be collected into a tube containing a nucleic acid stabilization solution (Allprotect Tissue reagent, Qiagen).~The nucleic acids will be extracted and then sequenced. The sequencing technology chosen (HaloPlexHS, Agilent) allows a detection close to 1% in allelic frequency. This new technical approach that links high sensitivity and specificity is also suitable with degraded and/or low-volume ( \<50ng) DNA."

Trial Locations (11)

13003

Hopital Europeen, Marseille

13008

Hopital Saint Joseph, Marseille

13385

Chu La Timone, Marseille

44000

CHU NANTES Institut des Maladies de l'Appareil Digestif, Nantes

69003

Hopital Edouard Herriot, Lyon

69008

Hopital Mermoz, Lyon

75014

Hopital Saint Joseph, Paris

87000

Centre Hospitalier Universitaire Dupuytren, Limoges

94220

Clinique de Bercy, Charenton-le-Pont

06200

Chu L'Archet 2, Nice

03207

Centre Hospitalier Jacques Lacarin, Vichy

All Listed Sponsors
collaborator

Ramsay Générale de Santé

OTHER

lead

Hospital St. Joseph, Marseille, France

OTHER

NCT03305146 - Feasibility of Molecular Biology in Pancreatic Cyst Tumors | Biotech Hunter | Biotech Hunter